Annexon (NASDAQ:ANNX) Hits New 1-Year Low – Time to Sell?

Annexon, Inc. (NASDAQ:ANNX – Get Free Report)’s share price hit a new 52-week low during trading on Friday. The company traded as low as $3.14 and last traded at $3.2450, with a volume of 348,991 shares trading hands. The stock had previously closed at $3.41.

Analyst Ratings Changes

Several research firms have weighed in on ANNX. JPMorgan Chase & Co. raised their price target on Annexon from $14.00 to $15.00 and gave the company an “overweight” rating in a report on Wednesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research report on Thursday, October 15th. Wall Street Zen downgraded Annexon from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Citizens Jmp raised shares of Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday, August 13th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $13.33.

Read Our Latest Research Report on Annexon

Annexon Price Performance

The company has a current ratio of 5.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $615.39 million, a PE ratio of -3.12 and a beta of 1.43. The stock’s 50-day moving average is $3.94 and its two-hundred day moving average is $5.05.

Annexon (NASDAQ:ANNX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.03. On average, equities analysts predict that Annexon, Inc. will post -1.03 EPS for the current year.

Insider Transactions at Annexon

In other Annexon news, CEO Douglas Love acquired 26,065 shares of the company’s stock in a transaction that occurred on Thursday, September 24th. The stock was bought at an average price of $3.83 per share, for a total transaction of $99,828.95. Following the acquisition, the chief executive officer directly owned 390,476 shares in the company, valued at $1,495,523.08. The trade was a 7.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 10.31% of the stock is currently owned by insiders.

Institutional Trading of Annexon

Several institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Annexon during the second quarter valued at $77,312,000. Redmile Group LLC grew its holdings in shares of Annexon by 44.8% in the first quarter. Redmile Group LLC now owns 14,549,768 shares of the company’s stock worth $80,606,000 after purchasing an additional 4,499,124 shares during the last quarter. Siren L.L.C. bought a new position in shares of Annexon in the first quarter worth about $21,931,000. Palo Alto Investors LP purchased a new position in Annexon in the 2nd quarter worth about $16,833,594. Finally, Bank of America Corp DE increased its stake in Annexon by 165.3% in the 1st quarter. Bank of America Corp DE now owns 4,259,995 shares of the company’s stock worth $23,600,000 after buying an additional 2,654,414 shares during the period.

Annexon Company Profile

(Get Free Report)

Annexon is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases driven by the complement system, a part of the immune system involved in inflammation and tissue damage. The company focuses on the classical complement pathway, which it aims to inhibit selectively. Its investigational programs are designed for complement-related autoimmune, inflammatory and neurodegenerative conditions. These include treatments being studied for disorders affecting the nervous system and the eye.

See Also

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.